FDA Approves Novocure’s Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer

On February 11, the FDA approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.

For more information, read the Novocure press release.

Posted on 2/13/2026